argenx SE

ARGX: XBRU (BEL)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
YP?LOCK|k$HLOCK|%wSSf^^

Argenx: Positive Vyvgart Data in Autoimmune Indication Supports Growth; FB102 Broadens Portfolio

Argenx announced positive top-line results from its phase 3 trial of Vyvgart in autoimmune myositis, or IIM, with the study meeting its primary endpoint at week 52 in the combined patient population of immune-mediated necrotizing myopathy and dermatomyositis. Shares soared 16% on Aug. 17.

Sponsor Center